Related Attributes
Product details
Lamivudine Raw Materials is a new type of antiviral drug, which belongs to nucleoside reverse transcriptase inhibitors, and has strong inhibitory effect on hepatitis B virus (HBV) in vitro and in experimentally infected animals, and can inhibit the synthesis of HIV virus; Lamivudine Raw Powder can be metabolised in HBV infected cells and normal cells.
Lamivudine Raw Powder can be metabolised in HBV-infected and normal cells to produce lamivudine triphosphate, the active form of lamivudine, which is an inhibitor of HBV polymerase and a substrate for this polymerase.Wholesale Lamivudine Raw Powder .
Uses and functions of Lamivudine Raw Powder.
Hepatitis B, Hepatitis B virus replication in chronic hepatitis B.
Pharmacological Effects of Lamivudine Powder.
Lamivudine Powder is metabolised in HBV-infected and normal cells to produce lamivudine triphosphate, the active form of Lamivudine Raw Powder, which is both an inhibitor of HBV polymerase and a substrate for this polymerase.
Serum HBV-DNA testing of most patients with hepatitis B showed no significant toxicity to mitochondrial structure, DNA content or function. It also reduces serum aminotransferases to normal, and long-term application can significantly improve necroinflammatory changes in the liver and reduce or stop the progression of hepatic fibrosis.
Lamivudine can rapidly inhibit HBV replication, and its inhibitory effect lasts throughout the treatment process.Lamivudine Raw Materials triphosphate is doped into the viral DNA strand, blocking the synthesis of viral DNA, and it does not interfere with the metabolism of deoxynucleoside in normal cells, and it has weak inhibitory effect on mammalian DNA polymerase α and β, and has almost no effect on the DNA content of mammalian cells.
The inhibitory effect on mammalian DNA polymerase α and β was weak, and the DNA content of mammalian cells was hardly affected.
Production method of Lamivudine Powder.
Lamivudine Powder was subjected to selective 6-O-sulfonylation reaction of compound (Ⅰ), followed by acetylation to obtain compound (Ⅱ) in 96.7% yield. Compound (II) was reacted with acetic acid as solvent and 3 moL of hydrogen bromide/L acid (45%, W/V) and brominated to give compound (III) in 99% yield. Bromide (III) and 3.3 moI.
potassium salt of ethyl xanthate, refluxed in acetone, were thiolated and cyclised; hydrolysis was then carried out in methanol with ammonia to give compound (IV) in 72% two-step yield. Compound (IV) was purified by column chromatography as a crystalline solid.
Why choose us?
HRK Factory
About Shipping
Pharmaceutical Intermediate manufacturers
©2022 Xi'an Henrikang Biotech Co., Ltd.,
Home
E-mail
Booking